Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
Last trade$0.2766
Day change-$0.0174 (-5.94%)
Day range$0.278 – $0.307
Volume123,205
Market cap$27M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$26.28M
Price / earnings
—
Price / book
7.57×
Price / sales
2.79×
EV / sales
2.62×
EV / EBITDA
-6.14×
Profitability
Earnings per share
-$0.05
Return on assets
-49.64%
Return on equity
-119.38%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.15×
Current ratio
1.85×
Quick ratio
1.14×
Cash ratio
0.47×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$657.76K
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MLSS, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$2.84M
$2.16M
$2.06M
$2.36M
$2.32M
$2.23M
$2.01M
$2.51M
Cost of revenue
$930.87K
$598.01K
$556.31K
$719.25K
$705.86K
$584.99K
$502.45K
$677.59K
Gross profit
$1.91M
$1.56M
$1.5M
$1.64M
$1.62M
$1.65M
$1.51M
$1.84M
Selling, general and administrative
$2.95M
$2.37M
$2.55M
$2.74M
$3.03M
$3.26M
$3.33M
$3.06M
Research and development
$6.61K
$0
$12.33K
$16.23K
$51.79K
$369.12K
$217.53K
$232.06K
Total operating expenses
$2.97M
$2.39M
$2.58M
$2.78M
$3.1M
$3.65M
$3.55M
$3.31M
Operating income
-$1.06M
-$828.08K
-$1.08M
-$1.13M
-$1.48M
-$2M
-$2.04M
-$1.47M
Interest expense
$2.23K
-$11.77K
$0
$0
$1.52K
$3.27K
$0
$0
Income before taxes
-$1.06M
-$839.85K
-$1.09M
-$1.15M
-$1.48M
-$1.99M
-$2.04M
-$1.46M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.06M
-$839.85K
-$1.09M
-$1.15M
-$1.48M
-$1.99M
-$2.04M
-$1.46M
Net income attributable to common shareholders
-$1.06M
-$839.85K
-$1.09M
-$1.15M
-$1.48M
-$1.99M
-$2.04M
-$1.46M
EBITDA
-$1.04M
-$808.63K
-$1.06M
-$1.11M
-$1.47M
-$1.98M
-$2.03M
-$1.46M
Basic earnings per share
-$0.01
-$0.01
-$0.01
-$0.01
-$0.02
-$0.02
-$0.03
-$0.02
Diluted earnings per share
-$0.01
-$0.01
-$0.01
-$0.01
-$0.02
-$0.02
-$0.03
-$0.02
Recent news
Company coverage with links to the original publishers.
Milestone Scientific Inc. (NYSE: MLSS), a developer of computerized drug delivery instruments, announced it will host a conference call on August 14, 2026, at 8:30 AM ET to discuss Q2 2026 financial results and corporate progress. The call will be available via telephone and webcast.
Milestone Scientific reported stable Q3 2025 revenues of $2.4 million, reduced operating expenses by over $500,000, and continued advancing its dental and medical segment strategies with focus on cost management and growth initiatives.
Milestone Scientific Inc. has appointed Shanth Thiyagalingam, a seasoned MedTech executive, to its Board of Directors. Thiyagalingam brings extensive experience in commercial leadership, reimbursement strategy, and global market insights, which will support Milestone's growth across medical and dental segments.
Milestone Scientific announced the commercial rollout of its CompuFlo® Epidural System at Advanced Spine and Pain Management, following a successful pilot program. The company also reported increasing adoption of the system after a Medicare price assignment, highlighting its clinical and economic benefits.
Milestone Scientific Inc., a medical technology company, announced that its CEO and Chairman will be presenting at The Benchmark Company's investor conference on December 11th, 2024. The conference offers emerging growth companies access to institutional and individual investors in a one-on-one format.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.